Prevention strategies for type 1 diabetes mellitus: Current status and future directions

BioDrugs

Volumn 17, Issue 1, 2003, Pages 39-64

  Winter, William E ^a   Schatz, Desmond ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; B7 ANTIGEN; CALCINEURIN INHIBITOR; CD20 ANTIGEN; CD3 ANTIGEN; CD52 ANTIGEN; CYCLOSPORIN; CYTOKINE; DACLIZUMAB; EPRATUZUMAB; ETANERCEPT; GLUCOCORTICOID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POLYCLONAL ANTIBODY; RAPAMYCIN; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; UNINDEXED DRUG; VACCINE;

ABDOMINAL PAIN; ACNE; ADOPTIVE IMMUNOTHERAPY; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; CONSTIPATION; CUSHING SYNDROME; DIARRHEA; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GENE THERAPY; GINGIVA HYPERPLASIA; HIRSUTISM; HUMAN; HYPERTENSION; HYPOKALEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; LEUKOPENIA; LIVER TOXICITY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL; RASH; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANTIBODIES; AUTOANTIBODIES; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS TRANSPLANTATION;

EID: 0037272161     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317010-00004     Document Type: Review

References (244)

1. Norris JM, Dorman JS, Rewers M, et al. The epidemiology and genetics of insulin-dependent diabetes mellitus. Arch Pathol Lab Med 1987; 111: 905-9
2. Dahlquist G. The aetiology of type 1 diabetes: an epidemiological perspective. Acta Paediatr Suppl 1998 Oct; 425: 5-10
3. Schatz DA, Bingley PJ. Update on major trials for the prevention of type 1 diabetes mellitus: the American Diabetes Prevention Trial (DPT-1) and the European Nicotinamide Diabetes Intervention Trial (ENDIT). J Pediatr Endocrinol Metab 2001; 14 Suppl. 1: 619-22
4. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25: S5-S20
5. Winter WE, Maclaren NK. Autoimmune endocrinopathies. In: Stiehm ER, editor. Immunologic disorders in infants and children. 4th ed. Philadelphia (PA): WB Saunders, 1996: 824-54
6. Kukreja A, Maclaren NK. Autoimmunity and diabetes. J Clin Endocrinol Metab 1999 Dec; 84 (12): 4371-8
7. Kawasaki E, Gill RG, Eisenbarth GS. Type 1 diabetes mellitus. In: Eisenbarth GS, editor. Endocrine and organ specific autoimmunity. Austin (TX); RG Landes, 1999: 149-82
8. Delves PJ, Roitt IM. The immune system: first of two parts. N Engl J Med 2000; 343 (1): 37-49
9. Delves PJ, Roitt IM. The immune system: second of two parts. N Engl J Med 2000; 343 (2): 108-17
10. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev 1998; 14: 129-51
11. Gepts W, Lecompte PM. The pancreatic islets in diabetes. Am J Med 1981; 70: 105-15
12. Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001 Oct 4; 345 (14): 1036-40
13. Marx J. Testing of autoimmune therapy begins. Science 1991; 252: 272-8
14. Cavanaugh J, Chopek M, Binimelis J, et al. Buffy coat transfusions in early type 1 diabetes. Diabetes 1987; 36 (10): 1089-93
15. Krug J, Verlohren HJ, Bierwolf B, et al. Lymphocyte transfusion in recent onset type 1 diabetes mellitus: a one-year follow-up of cell-mediated anti-islet cytotoxicity and C-peptide secretion. J Autoimmun 1990; 3 (5): 601-9
16. Dempe A, Baaske W, von-Baehr R, et al. Remission of the newly diagnosed type 1 diabetes by radiation of the pancreas. Exp Clin Endocrinol 1988; 92 (1): 123-5
17. Rand KH, Rosenbloom AL, Maclaren NK, et al. Human leukocyte interferon treatment of two children with insulin-dependent diabetes. Diabetologia 1981; 21: 116-9
18. Koivisto VA, Aro A, Cantell K, et al. Remissions in newly diagnosed Type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy. Diabetologia 1984 Aug; 27 (2): 193-7
19. Cobb WE, Molitch M, Reichlin S. Levamisole in insulin-dependent diabetes mellitus. N Engl J Med 1980; 303: 1065-6
20. Shehadeh N, Calcinaro F, Bradley BJ, et al. Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 1994; 343 (8899): 706-7
21. Pozzilli P. BCG vaccine in insulin-dependent diabetes mellitus. 1MDIAB Group. Lancet 1997 May 24; 349 (9064): 1520-1
22. Allen HF, Klingensmith GJ, Jensen P, et al. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes: a randomized clinical study. Diabetes Care 1999 Oct; 22 (10): 1703-7
23. Usadel KH, Teuber J, Schmeidl R, et al. Management of type 1 diabetes with ciamexone [letter]. Lancet 1986; II (8506): 567
24. Giordano C, Panto F, Amato MP, et al. Early administration of an immunomodulator and induction of remission in insulin-dependent diabetes mellitus. J Autoimmun 1990; 3 (5): 611-7
25. Moncada E, Subira ML, Oleaga A, et al. Insulin requirements and residual beta-cell function 12 months after concluding immunotherapy in type 1 diabetic patients treated with combined azathioprine and thymostimulin administration for one year. J Autoimmun 1990; 3 (5): 625-38
26. Ludvigsson J, Samuelsson U, Ernerudh J, et al. Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial. Arch Dis Child 2001 Aug; 85 (2): 149-54
27. Riley WJ, Maclaren NK, Spillar RS. Reversal of deteriorating glucose tolerance with azathioprine in pre-diabetes. Transplant Proc 1986; 18 (4): 819-22
28. Silverstein J, Maclaren N, Riley W, et al. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988; 319: 599-604
29. Stiller CR, Dupre J, Gent M, et al. Effects of cyclosporin immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984; 223: 1362-7
30. Assan R, Feutren G, Debray-Sachs M, et al. Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus. Lancet 1985; 1: 67-71
31. Feutren G, Papoz L, Assan R, et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multi-centre double-blind trial. Lancet 1986; II (8499): 119-24
32. Dupre J, Stiller CR, Gent M, et al. Clinical trials of cyclosporin in IDDM. Diabetes Care 1988; II (1 Suppl.): 37-44
33. Bougneres PF, Carel JC, Castano L, et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1990; 318: 663-70
34. Chase HP, Butler-Simon N, Garg SK, et al. Cyclosporine A for the treatment of new-onset insulin-dependent diabetes mellitus. Pediatrics 1990; 85 (3): 241-5
35. Drash AL. Is it time to draw the curtain on immune intervention trials in newly diagnosed patients with IDDM? Diabetes Care 1995; 18: 1499-501
36. Ramsdell F, Fowlkes BJ. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science 1990; 248: 1342-8
37. Ramiya VK, Shang XZ, Wasserfall CH, et al. Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoimmunity 1997: 26 (3): 139-51
38. Chatenoud L. Use of CD3 antibodies in transplantation and atttoimmune diseases. Transplant Proc 1994 Dec; 26 (6): 3191-3
39. Ahdoot J, Galindo A, Alejos JC, et al. Use of OKT3 for acute myocarditis in infants and children. J Heart Lung Transplant 2000 Nov; 19 (11): 118-21
40. Henrickson M, Giannini EH, Hirsch R. Reduction of mortality and lymphadenopathy in MRL-lpr/lpr mice treated with nonmitogenic anti-CD3 monoclonal antibody. Arthritis Rheum 1994 Apr; 37 (4): 587-94
41. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992 Mar; 41 (3): 385-91
42. Chatenoud L, Thervet E, Primo J, et al. Remission of established disease in diabetic NOD mice induced by anti-CD3 monoclonal antibody. C R Acad Sci III 1992: 315 (6): 225-8
43. Chatenoud L, Thervet E, Primo J, et al. Anti-CD3 antibody reduces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994 Jan 4; 91 (1): 123-7
44. Friend PJ, Hale G, Chatenoud L, et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999 Dec 15; 68 (11): 1632-7
45. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gammal (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999 Sep 15; 68 (5): 608-16
46. Xu D, Alegre ML, Varga SS, et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000 Feb 25; 200 (1): 16-26
47. Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gammal (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999 Sep 15; 68 (5): 608-16
48. Waldmann TA, Levy R, Coller BS. Emerging therapies: spectrum of applications of monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program) 2000; 394-408
49. Jackson RA, Morris MA, Haynes BF, et al. Increased circulating Ia-antigen-bearing T cells in type 1 diabetes mellitus. N Engl J Med 1982 Apr 1; 306 (13): 785-8
50. Brok HP, Tekoppele JM, Hakimi J, et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol 2001 Apr; 124 (1): 134-41
51. Egan CA, Brown M, White JD, et al. Treatment of epidermolysis bullosa acquisita with the humanized anti-Tac mAb daclizumab. Clin Immunol 2001 Nov; 101 (2): 146-51
52. Krueger JG, Walters IB, Miyazawa M, et al. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 2000 Sep; 43 (3): 448-58
53. Nussenblatt RB, Fortin E, Schiffman R, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 1999 Jun 22; 96 (13): 7462-6
54. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 Jul 27; 343 (4): 230-8
55. Bruce DS, Sollinger HW, Humar A, et al. Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation 2001 Nov 27; 72 (10): 1637-43
56. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg 2001 Apr; 233 (4): 463-501
57. Papiernik M, de Moraes ML, Pontoux C, et al. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998 Apr; 10 (4): 371-8
58. Bach JF, Chatenoud L. Tolerance to islet autoantigens in type 1 diabetes. Annu Rev Immunol 2001; 19: 131-61
59. Kingsley CI, Karim M, Bushell AR, et al. CD25 (+)CD4 (+) regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol 2002 Feb 1; 168 (3): 1080-6
60. Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25 (+)CD4 (+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000 Jul 17; 192 (2): 303-10
61. Chatenoud L, Salomon B, Bluestone JA. Suppressor T cells: they're back and critical for regulation of autoimmunity! Immunol Rev 2001 Aug; 182: 149-63
62. Stephens LA, Mason D. CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found ill both CD25+ and CD25- subpopulations. J Immunol 2000 Sep 15: 165 (6): 3105-10
63. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000 Apr; 12 (4): 431-40
64. Nelson DR, Soldevila-Pico C, Reed A, et al. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation. Liver Transpl 2001 Dec; 7 (12): 1064-70
65. Berard JL, Velez RL, Freeman RB, et al. A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy 1999 Oct; 19 (10): 1127-37
66. Pangalis GA, Dimopouloa MN, Angelopoulou MK, et al. Campatb-IH (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001; 18 (2): 99-107
67. White CA, Weaver RL, Grillo-Lopez AJ. Antibody-targeted immunotherapy for treatment of malignancy. Annu Rev Med 2001; 52: 125-45
68. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000 Nov; 12 (6): 574-81
69. Diekman AB, Norton EJ, Westbrook VA, et al. Anti-sperm antibodies from infertile patients and their cognate sperm antigens: a review. Identity between SAGA-1, the H6-3C4 antigen, and CD52. Am J Reprod Immunol 2000 Mar; 43 (3): 134-43
70. Domagala A, Kurpisz M. CD52 antigen: a review. Med Sci Monit 2001 Mar-Apr; 7 (2): 325-31
71. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999 Nov 13; 354 (9191): 1691-5
72. Lim SH, Hale G, Marcus RE, et al. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 1993 Jul; 84 (3): 542-4
73. Sanders ME. Clinical trial of chimeric anti-CD4-monoclonal antibody for insulin dependent diabetes mellitus [letter]. Diab Prev Ther 1991; 5: 28
74. Skyler JS, Lorenz TJ, Schwartz S, et al. Effects of an anti-CD5 immunoconjugate (CD5-plus) in recent onset type 1 diabetes mellitus: a preliminary investigation. The CD5 Diabetes Project Team. J Diabetes Complications 1993; 7 (4): 224-32
75. Vialettes B, Vague P. Treatment of diabetes by monoclonal antibodies: lessons from a pilot study using anti-IL-2 receptor MoAb in recently diagnosed diabetic patients. Diab Prev Ther 1991; 5: 21-2
76. Culler FL, O'Connor R, Kaufmann S, et al. Immunospecific therapy for type 1 diabetes mellitus. N Engl J Med 1985; 313 (11): 695-6
77. Bach JF, Feutren G, Boitard C. Immunoprevention of insulin-dependent diabetes by cyclosporin. In: Andreani D, Kolb H, Pozzilli P, editors. Immunotherapy of type I diabetes. Chichester: John Wiley & Sons. 1989: 125-36
78. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999 Nov; 58 Suppl. 1: 165-9
79. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002 Jan; 109 (1): 109-15
80. Bloom BJ. Development of diabetes mellitus during etanercept therapy in a child with systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000 Nov; 43 (11): 2606-8
81. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001 Dec; 44 (12): 2862-9
82. Silverstein J, Riley W, Barrett D, et al. Immnnosuppressive therapy (IT) for newly diagnosed insulin dependent diabetes mellitus (IDD) with antithymocyte globulin (ATG) and prednisone (pred) [abstract]. Pediatr Res 1984; 71: 295A
83. Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis: results of a 10-year prospective study. Rheumatology (Oxford) 2001 Aug; 40 (8): 907-13
84. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001 Jun; 46 (6): 1321-7
85. Hern S, Harman K, Bhogal BS, et al. A severe persistent case of pemphigoid gestationis treated with intravenous immunoglobulins and cyclosporin. Clin Exp Dermatol 1998 Jul; 23 (4): 185-8
86. Loria MP, Dambra PP, D'Oronzio L, et al. Cyclosporin A in patients affected by chronic idiopathic urticaria: a therapeutic alternative. Immunopharmacol Immunotoxicol 2001 May; 23 (2): 205-13
87. Gesundheit B, Cividalli G, Freeman A, et al. Cyclosporin A in the treatment of refractory immune thrombocytopenia purpura in children. Eur J Haematol 2001 May; 66 (5): 347-51
88. Hyde GM, Jewell DP, Kettlewell MG, et al. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001 Oct; 44 (10): 1436-40
89. Spring PJ, Spies JM. Myasthenia gravis: options and tinting of immunomodulatory treatment. BioDrugs 2001; 15 (3): 173-83
90. Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis 2002 Jan; 61 (1): 37-41
91. Anstey A, Mayou S, Morgan K, et al. Relapsing polychondritis: autoimmunity to type II collagen and treatment with cyclosporin A. Br J Dermatol 1991 Dec; 125 (6): 588-91
92. Griffiths B, Emery P. The treatment of lupus with cyclosporin A. Lupus 2001; 10 (3): 165-70
93. Kulkarni P. Review: uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther 2001 Apr; 17 (2): 181-7
94. Martin S, Schernthaner G, Nerup J, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34 (6): 429-34
95. Marks JB, Skyler JS. Clinical review 17: immunotherapy of type I diabetes mellitus. J Clin Endocrinol Metab 1991; 72 (1): 3-9
96. Carroll PB, Tzakis AG, Ricordi C, et al. The use of FK 506 in new-onset type I diabetes in man. Transplant Proc 1991; 23 (6): 3351-3
97. Yoshioka K, Sato T, Okada N, et al. Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Diabetes Res Clin Pract 1998 Nov; 42 (2): 85-9
98. Maes BD, Kuypers D, Messiaen T, et al. Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001 Nov 27; 72 (10): 1655-61
99. Damoiseaux JG, van Breda Vriesman PJ. Cyclosporin A-induced autoimmnnity: the result of defective de novo T-cell development. Folia Biol (Praha) 1998; 44 (1): 1-9
100. Lohmann T, List C, Lamesch P, et al. Diabetes mellitus and islet cell specific autoimmunity as adverse effects of immunsuppressive therapy by FK506/tacrolimus. Exp Clin Endocrinol Diabetes 2000; 108 (5): 347-52
101. Aspeslet L, Freitag D, Trepanier D, et al. ISA (TX)247: a novel calcineurin inhibitor. Transplant Proc 2001 Feb-Mar; 33 (1-2): 1048-51
102. Benhamou PY. Immunomodulation with CTLA4-Ig in islet transplantation. Transplantation 2002 Jan 15; 73 (1 Suppl.): S40-2
103. Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant 1997 Sep-Oct; 6 (5): 505-8
104. Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated rabbit islet xenografts in spontaneously diabetic NOD mice. Transplant Proc 1996 Apr; 28 (2): 821-3
105. Reynolds J, Tam FW, Chandraker A, et al. CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J Clin Invest 2000 Mar; 105 (5): 643-51
106. Croxford JL, O'Neill JK, Ali RR, et al. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 1998 Dec; 28 (12): 3904-16
107. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997 Aug 5; 94 (16): 8789-94
108. Elliott RB, Crossley JR, Berryman CC, et al. Partial preservation of pancreatic β-cell function in children with diabetes. Lancet 1981; 2: 1-4
109. Jackson R, Dolinar R, Srikanta S, et al. Prednisone therapy in early type I diabetes: immunological effects [abstract]. Diabetes 1982; 31: 48A
110. Ludvigsson J, Heding L, Lernmark A, et al. An attempt to break the autoimmune process at the onset of IDDM by the use of plasmapheresis and high doses of prednisolone. Bulletin of the International Study Group for Diabetes in the Young 1982; 6: 11-2
111. Baeder WL, Sredy J, Sehgal SN, et al. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992 Aug; 89 (2): 174-8
112. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, et al. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002 Mar; 51 (3): 638-45
113. Harrison LC, Colman PG, Dean B, et al. Increase in remission rate in newly diagnosed type 1 diabetic subjects treated with azathioprine. Diabetes 1985; 34: 1306-8
114. Cook JJ, Hudson I, Harrison LC, et al. Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes. Diabetes 1989 Jun; 38 (6): 779-83
115. Sutherland DE, Gruessner RW, Gruessner AC. Pancreas transplantation for treatment of diabetes mellitus. World J Surg 2001 Apr; 25 (4): 487-96
116. Megahed M, Schmiedeberg S, Becket J. et al. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol 2001 Aug; 45 (2): 256-9
117. Zierhut M, Stubiger N, Aboalchamat W, et al. Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis. Ophthalmologe 2001 Jul; 98 (7): 647-51
118. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001 Jul; 45 (1): 142-4
119. Miehsler W, Reinisch W, Moser G, et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001 Mar; 96 (3): 782-7
120. Geilen CC, Arnold M, Orfanos CE. Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 patients. Br J Dermatol 2001 Mar; 144 (3): 583-6
121. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000 Sep; 33 (3): 371-5
122. Hao L, Chan SM, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann N Y Acad Sci 1993 Nov 30; 696: 328-32
123. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
124. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
125. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective diabetes study (UKPDS) Group. Lancet 1998; 352: 854-65
126. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
127. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care 1998; 21 (12): 2180-4
128. Nydegger UE, Sturzenegger T. Treatment of autoimmune disease: synergy between plasma exchange and intravenous immunoglobulins. Ther Apher 2001 Jun; 5 (3): 186-92
129. Leslie RDG, Pyke DA. Immunosuppression of acute insulin-dependent diabetes. In: Irvine WJ, editor. The immunology of diabetes. Edinburgh: Tevoit Scientific Publications, 1980: 345-7
130. Ludvigsson J, Heding L, Gudrun L, et al. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. BMJ 1983; 286: 176-8
131. Pocecco M, De-Campo C, Cantoni L, et al. Effect of high doses intravenous IgG in newly diagnosed diabetic children. Helv Paediatr Acta 1987; 42 (4): 289-95
132. Colagiuri S, Leong GM, Thayer Z, et al. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol 1996 May-Jun; 14 Suppl. 15: S93-7
133. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998 Apr 15; 55 (8): 1139-49
134. Slavin AJ, Maron R, Weiner HL. Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes. Int Immunol 2001 Jun; 13 (6): 825-33
135. Boitard C, Timsit J, Assan R, et al. Treatment of type 1 diabetes mellitus with DAB486-IL-2, a toxin conjugate which targets activated T-lymphocytes [abstract]. Diabetologia 1992; 35 Suppl. 1: A218
136. Pacheco-Silva A, Bastos MG, Muggia RA, et al. Interleukin 2 receptor targeted fusion toxin (DAB486-IL-2) treatment blocks diabetogenic autoimmunity in non-obese diabetic mice. Eur J Immunol 1992 Mar; 22 (3): 697-702
137. Jacob CO, Aiso S, Michie SA, et al. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A 1990 Feb; 87 (3); 968-72
138. Ranieri E, Herr W, Gambotto A, et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol 1999 Dec; 73 (12): 10416-25
139. Tarner IH, Fathman CG. Gene therapy in autoimmune disease. Curr Opin Immunol 2001 Dec; 13 (6): 676-82
140. Coates PT, Krishnan R, Kireta S, et al. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther 2001 Aug; 8 (16): 1224-33
141. Ellem KA, O'Rourke MG, Johnson GR, et al. A case report: immune responses and clinical coarse of the first haman use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997 Mar; 44 (1): 10-20
142. Gross DJ, Weiss L, Reibstein I, et al. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. Int Immunopharmacol 2001 Jun; 1 (6): 1131-9
143. Martin S, van den Engel NK, Vinke A, et al. Dominant role of intercellular adhesion molecule-1 in the pathogenesis of autoimmune diabetes in non-obese diabetic mice. J Autoimmun 2001 Sep; 17 (2): 109-17
144. Bertera S, Alexander A, Giannoukakis N, et al. Immunology of type 1 diabetes: intervention and prevention strategies. Endocrinol Metab Clin North Am 1999 Dec; 28 (4): 841-64
145. Lin-Su K, Kukreja A, Maclaren NK. Diabetes vaccines: a future to be realized. Diabetes Technol Ther 2001 Fall; 3 (3): 451-61
146. Smith KM, Eaton AD, Finlayson LM, et al. Oral tolerance. Am J Respir Crit Care Med 2000 Oct; 162 (4 Pt 2): S175-8
147. Weiner HL. Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 2001 Sep; 3 (11): 947-54
148. Komagata Y, Weiner HL. Oral tolerance. Rev Immunogenet 2000; 2 (1): 61-73
149. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit Rev Immunol 2000; 20 (1): 1-16
150. Gotfredsen GF, Buschard K, Frandsen EK. Redaction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985; 28: 933-5
151. Polanski M, Melican NS, Zhang J, et al. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer model of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997 Aug; 10 (4): 339-46
152. Ma S, Jevnikar AM. Autoantigens produced in plants for oral tolerance therapy of autoimmune diseases. Adv Exp Med Biol 1999; 464: 179-94
153. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993; 341: 927-8
154. Haist RE, Campbell J, Best CH. The prevention of diabetes. N Engl J Med 1940; 223: 607-15
155. Fuchtenbusch M, Rabl W, Grassl B, et al. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998 May; 41 (5): 536-41
156. The effects of insulin relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002; 346: 1685-91
157. Hanninen A, Harrison LC. Gamma delta T cells as mediators of mucosal tolerance: the autoimmune diabetes model. Immunol Rev 2000 Feb; 173: 109-19
158. Daniel D, Wegmann DR. Intranasal administration of insulin peptide B: 9-23 protects NOD mice from diabetes. Ann N Y Acad Sci 1996 Feb 13; 778: 371-2
159. Tian J, Atkinson MA, Clare-Salzler M, et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996 Apr 1; 183 (4): 1561-7
160. Pozzilli P, Pitocco D, Visalli N, et al. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia 2000 Aug; 43 (8): 1000-4
161. Karjalainen J, Martin JM, Knip M, et al. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 1992 Jul 30; 327 (5): 302-7
162. Norris J, Pietropaolo M. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. J Endocrinol Invest 1994 Jul-Aug; 17 (7): 565-72
163. Karlsson MG, Ludvigsson J. The ABBOS-peptide from bovine serum albumin causes an IFN-gamma and IL-4 mRNA response in lymphocytes from children with recent onset of type 1 diabetes. Diabetes Res Clin Pract 2000 Mar; 47 (3): 199-207
164. Atkinson MA, Winter WE, Skordis N, et al. Dietary protein restriction reduces the frequency and delays the onset of insulin dependent diabetes m BB rats. Autoimmunity 1988; 2: 11-20
165. Maclaren NK, Atkinson MA. Is insulin-dependent diabetes mellitus environmentally induced? N Engl J Med 1992; 327: 347-9
166. Akerblom HK, Knip M. Putative environmental factors in type 1 diabetes. Diabetes Metab Rev 1998; 14: 31-67
167. Couper JJ, Steele C, Beresford S, et al. Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity, Diabetes 1999; 48 (11): 2145-9
168. Hummel M, Fachtenbasch M, Schenker M, et al. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 2000; 23 (7): 969-74
169. Hanninen A. Prevention of autoimmune type 1 diabetes via mucosal tolerance: is mucosal autoantigen administration as safe and effective as it should be? Scand J Immunol 2000 Sep; 52 (3): 217-25
170. Pozzilli P, Gisella Cavallo M. Oral insulin and the induction of tolerance in man: reality or fantasy? Diabetes Metab Res Rev 2000 Sep-Oct; 16 (5): 306-7
171. Balasa B, Boehm BO, Fortnagel A, et al. Vaccination with glutamic acid decarboxylase plasmid DNA protects mice from spontaneous autoimmune diabetes and B7/CD28 costimulation circumvents that protection. Clin Immunol 2001 May; 99 (2): 241-52
172. Menard V, Jacobs H, Jun HS, et al. Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice. Pharm Res 1999 Jul; 16 (7): 1059-66
173. Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996 Dec; 2 (12): 1348-53
174. Sai P, Rivereau AS, Granier C, et al. Immunization of non-obese diabetic (NOD) mice with glutamic acid decarboxylase-derived peptide 524-543 reduces cyclophosphamide-accelerated diabetes. Clin Exp Immunol 1996 Aug; 105 (2): 330-7
175. Wilson SS, White TC, DeLuca D. Therapeutic alteration of insulin-dependent diabetes mellitus progression by T cell tolerance to glutamic acid decarboxylase 65 peptides in vitro and in vivo. J Immunol 2001 Jul 1; 167 (1): 569-77
176. Pleau JM, Fernandez-Saravia F, Esling A, et al. Prevention of autoimmune diabetes in nonobese diabetic female mice by treatment with recombinant glutamic acid decarboxylase (GAD 65). Clin Immunol Immunopathol 1995 Jul; 76 (1 Pt 1): 90-5
177. Geng L, Solimena M, Flavell RA, et al. Widespread expression of an autoantigen-GAD65 transgene does not tolerize non-obese diabetic mice and can exacerbate disease. Proc Natl Acad Sci U S A 1998 Aug 18; 95 (17): 10055-60
178. Jones DB, Hunter NR, Duff GW. Heat-shock protein 65 as a beta cell antigen of insulin-dependent diabetes. Lancet 1990 Sep 8; 336 (8715): 583-5
179. Atkinson MA, Holmes LA, Scharp DW, et al. No evidence for serological autoimmunity to islet cell heat shock proteins in insulin dependent diabetes. J Clin Invest 1991 Feb; 87 (2): 721-4
180. Elias D, Reshef T, Birk OS, et al. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci U S A 1991 Apr 15; 88 (8): 3088-91
181. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994 Mar 19; 343 (8899): 704-6
182. Funds DP, Hartoft-Nielsen ML, Kaas A, et al. Effect of intrathymic administration of mycobacterial heat shock protein 65 and peptide p277 on the development of diabetes in NOD mice: caution required in vaccination studies.
183. Elias D, Marcus H, Reshef T, et al. Induction of diabetes in standard mice by immunization with the p277 peptide of a 60-kDa heat shock protein. Eur J Immunol 1995 Oct; 25 (10): 2851-7
184. Elias D, Meilin A, Ablamunits V, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997 May; 46 (5): 758-64
185. Ablamunits V, Elias D, Reshef T, et al. Islet T cells secreting IFN-gamma in NOD mouse diabetes: arrest by p277 peptide treatment. J Autoimmun 1998 Feb; 11 (1): 73-81
186. Bockova J, Elias D, Cohen IR. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces antibodies. J Autoimmun 1997 Aug; 10 (4): 323-9
187. Abulafia-Lapid R, Elias D, Raz I, et al. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999 Mar; 12 (2): 121-9
188. Harkonen T, Puolakkainen M, Sarvas M, et al. Picornavirus proteins share antigenic determinants with heat shock proteins 60/65. J Med Virol 2000 Nov; 62 (3): 383-91
189. Quintana FJ, Rotem A, Carmi P, et al. Vaccination with empty plasmid DNA or CpG oligonucleotide inhibits diabetes in nonobese diabetic mice: modulation of spontaneous 60-kDa heat shock protein autoimmunity. J Immunol 2000 Dec 1; 165 (11): 6148-55
190. Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001 Nov 24; 358 (9295): 1749-53
191. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14: 1-27
192. Alleva DG, Crowe PD, Jin L, et al. A disease-associated cellular immune response in type 1 diabetics to an mmunodominant epitope of insulin. J Clin Invest 2001 Jan; 107 (2): 173-80
193. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B- (9-23). Proc Natl Acad Sci U S A 1996 Jan 23; 93 (2): 956-60
194. Johnson KP. A review of the clinical efficacy profile of copolymer 1: new US phase III trial data. J Neurol 1996 Apr; 243 (4 Suppl. 1): S3-7
195. Zhang M, Chan CC, Vistica B, et al. Copolymer 1 inhibits experimental autoimmune uveoretinitis. J Neuroimmunol 2000 Mar 1; 103 (2): 189-94
196. Pozzilli P, Visalli N, Ghirlanda G, et al. Nicotinamide increases C-peptide secretion in patients with recent onset type 1 diabetes. Diabet Med 1989 Sep-Oct; 6 (7): 568-72
197. Mendola G, Casamitjana R, Gomis R. Effect of nicotinamide therapy upon B-cell function in newly diagnosed type 1 (insulin-dependent) diabetic patients. Diabetologia 1989 Mar; 32 (3): 160-2
198. Vague P, Picq R, Bernal M, et al. Effect of nicotinamide treatment on the residual insulin secretion in type 1 (insulin-dependent) diabetic patients. Diabetologia 1989 May; 32 (5): 316-21
199. Bingley PJ, Caldas G, Bonfanti R, et al. Nicotinamide and insulin secretion in normal subjects. Diabetologia 1993 Jul; 36 (7): 675-7
200. Visalli N, Cavallo MG, Signora A, et al. A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset type 1 diabetes (the IMDIAB VI). Diabetes Metab Res Rev 1999 May-Jun; 15 (3): 181-5
201. Greenbaum CJ, Kahn SE, Palmer JP. Nicotinamide's effects on glucose metabolism in subjects at risk for IDDM. Diabetes 1996 Nov; 45 (11): 1631-4
202. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: a review. Diabetologia 2000 Nov; 43 (11): 1337-45
203. Kolb H, Burkart V. Nicotinamide in type 1 diabetes: mechanism of action revisited. Diabetes Care 1999 Mar; 22 Suppl. 2: B16-20
204. Kretowski A, Mysliwiec J, Szelachowska M, et al. Nicotinamide inhibits enhanced in vitro production of interleukin-12 and tumour necrosis factor-alpha in peripheral whole blood of people at high risk of developing type 1 diabetes and people with newly diagnosed type 1 diabetes. Diabetes Res Clin Pract 2000 Feb; 47 (2): 81-6
205. Hoorens A, Pipeleers D. Nicotinamide protects human beta cells against chemically-induced necrosis, but not against cytokine-induced apoptosis. Diabetologia 1999 Jan; 42 (1): 55-9
206. Reddy S, Karanam M, Robinson E. Prevention of cyclophosphamide-induced accelerated diabetes in the NOD mouse by nicotinamide or a soy protein-based infant formula. Int J Exp Diabetes Res 2001; 1 (4): 299-313
207. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34 (5): 362-5
208. Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996 Sep-Oct; 9 (5): 501-9
209. Manna R, Migliore A, Martin LS, et al. Nicotinamide treatment in subjects at high risk of developing IDDM improves insulin secretion. Br J Clin Pract 1992; 46 (3): 1-9
210. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 1995 Jul; 38 (7): 848-52
211. Pozzilli P, Visalli N, Boccuni ML, et al. Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study. Diabetes Care 1994 Aug; 17 (8): 897-900
212. Herskowitz RD, Jackson RA, Soeldner JS, et al. Pilot trial to prevent type 1 diabetes: progression to overt IDDM despite oral nicotinamide. J Autoimmun 1989; 2 (5): 733-7
213. Chase HP, Butler-Simon N, Garg S, et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990 Jul; 33 (7): 444-6
214. Lewis CM, Canafax DM, Sprafka JM, et al. Double-blind randomized trial of nicotinamide on early-onset diabetes. Diabetes Care 1992 Jan; 15 (1): 121-3
215. Taboga C, Tonutti L, Noacco C. Residual B cell activity and insulin requirements in insulin-dependent diabetic patients treated from the beginning with high doses of nicotinamide: a two-year follow-up. Recenti Prog Med 1994 Nov; 85 (11): 513-6
216. Vidal J, Fernandez-Balsells M, Sesmilo G, et al. Effects of nicotinamide and intravenous insulin therapy in newly diagnosed type 1 diabetes. Diabetes Care 2000 Mar; 23 (3): 360-4
217. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998 Jun; 47 (6): 980-4
218. Vialettes B, Picq R, du Rostu M, et al. A preliminary multicentre study of the treatment of recently diagnosed type 1 diabetes by combination nicotinamidecyclosporin therapy. Diabet Med 1990 Sep-Oct; 7 (8): 731-5
219. Pozzilli P, Visalli N, Cavallo MG, et al. Vitamin E and mcotinamide have similar effects in maintaining residual beta cell function in recent onset insulin-dependent diabetes (the IMDIAB IV study). Eur J Endocrinol 1997 Sep; 137 (3): 234-9
220. Ho E, Bray TM, Antioxidants, NFkappaB activation, and diabetogenesis. Proc Soc Exp Biol Med 1999 Dec; 222 (3): 205-13
221. Hotta M, Tashiro F, Ikegami H, et al. Pancreatic beta cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J Exp Med 1998 Oct 19; 188 (8): 1445-51
222. Rabinovitch A, Suarez WL, Power RF. Lazaroid antioxidant reduces incidence of diabetes and insulitis in nonobese diabetic mice. J Lab Clin Med 1993 Apr; 121 (4): 603-7
223. Polo V, Saibene A, Pontiroli AE. Nicotinamide improves insulin secretion and metabolic control in lean type 2 diabetic patients with secondary failure to sulphonylureas. Acta Diabetol 1998 Apr; 35 (1): 61-4
224. Drash AL, Rudert WA, Borquaye S, et al. Effect of probucol on development of diabetes mellitus in BB rats. Am J Cardiol 1988 Jul 25; 62 (3): 27B-30B
225. Beales PE, Williams AJ, Albertini MC, et al. Vitamin E delays diabetes onset in the non-obese diabetic mouse. Horm Metab Res 1994 Oct; 26 (10): 450-2
226. Cornelius JG, Luttge BG, Peck AB. Antioxidant enzyme activities in IDD-prone and IDD-resistant mice: a comparative study. Free Radic Biol Med 1993 Apr; 14 (4): 409-20
227. Rocic B, Vucic M, Knezevic-Cuca J, et al. Total plasma antioxidants in first-degree relatives of patients with insulin-dependent diabetes. Exp Clin Endocrinol Diabetes 1997; 105 (4): 213-7
228. Robertson RP, Holohan TV, Genuth S. Therapeutic controversy: pancreas transplantation for type I diabetes. J Clin Endocrinol Metab 1998 Jun; 83 (6): 1868-74
229. Ricordi C. Human islet cell transplantation: new perspectives for an old challenge. Diab Reviews 1996; 4 (3): 356-69
230. Ramiya VK, Maraist M, Arfors KE, et al. Reversal of insulin-dependent diabetes using islets generated in vitro from pancreatic stem cells. Nat Med 2000 Mar; 6 (3): 278-82
231. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001 Apr; 50 (4): 710-9
232. Davalli AM, Maffi P, Socci C, et al. Insights from a successful case of intrahepatic islet transplantation into a type 1 diabetic patient. J Clin Endocrinol Metab 2000 Oct; 85 (10): 3847-52
233. Rafaeloff R, Pittenger GL, Barlow SW, et al. Cloning and sequencing of the pancreatic islet neogenesis associated protein (INGAP) gene and its expression in islet neogenesis in hamsters. J Clin Invest 1997 May 1; 99 (9): 2100-9
234. Giannoukakis N, Rudert WA, Robbins PD, et al. Targeting autoimmune diabetes with gene therapy. Diabetes 1999 Nov; 48 (11): 2107-21
235. Winter WE, House DV, Schatz D. Pharmacologic approaches to the prevention of autoimmune diabetes. Drugs 1997; 53 (6): 943-56
236. Imagawa A, Hanafusa T, Tamura S, et al. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001 Jun; 50 (6): 1269-73
237. Greiner DL, Rossini AA, Mordes JP. Translating data from animal models into methods for preventing human autoimmune diabetes mellitus: caveat emptor and primum non nocere. Clin Immunol 2001 Aug; 100 (2): 134-43
238. Rosenbloom AL, Schatz DA, Krischer JP, et al. Therapeutic controversy: prevention and treatment of diabetes in children. J Clin Endocrinol Metab 2000 Feb; 85 (2): 494-522
239. Vinik A, Pittenger G, Rafaeloff R, et al. Determinants of pancreatic islet cell mass: a balance between nesis and senescence/apoptosis. Diabet Rev 1996; 4 (2): 235-63
240. Funda DP, Kaas A, Bock T, et al. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 1999 Sep-Oct; 15 (5): 323-7
241. Pozzilli P. Prevention of insulin-dependent diabetes mellitus 1998. Diabetes Metab Rev 1998 Mar; 14 (1): 69-84
242. Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 1989 Mar 2; 320 (9): 550-4
243. Buyukgebiz A, Cemeroglu AP, Bober E, et al. Factors influencing remission phase in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001 Nov-Dec; 14 (9): 1585-96
244. Atkinson MA, Eisenbarth GS. Type I diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001 Jul 21; 358 (9277): 221-9